Walkers gather to fight ALS
ASHTABULA — Lisa Hughart was a regular at sporting events for the last 30 years, supporting her children, then grandchildren.
Dozens of people came to honor her and raise money to fight the deadly disease Amyotrophic Lateral Sclerosis, a progressive neurological disease often referred to as ALS.
Tim Hughart organized the event at Lake Shore Park Saturday morning to raise funds to fight the deadly disease. He said all proceeds would be given to the ALS Society, which is dedicated to finding a cure.
ALS is also often described as Lou Gehrig's disease in reference to the famous New York Yankee who was diagnosed with it in 1939 and died less than two years later.
The ALS Society website details ways in which the organization supports those with the disease and works to fund research to find a cure.
Tim Hughart said his wife was diagnosed in summer 2024 and died in November.
'She lasted only four months,' he said.
He sold shirts to raise money, as well as having a 50-50 raffle and a bake sale.
Walkers donated to the cause after they walked a loop of Lake Shore Park.
Lisa Hughart's son, Solomon Thomas, said he was deeply appreciative so many people took time out of their busy schedules to remember his mother and fight the disease.
He said it was hard to take in all the emotions surrounding the event. Many of the participants wore red shirts with Lisa Hughart's picture on the front, proclaiming ALS Awareness.
Several participants came to the march to represent those that have been battling the disease for many years.
The disease affects nerve cells in the brain and the spinal cord, making normal tasks very difficult as it progresses.
The ALS Society website seeks to walk newly-diagnosed people through the process.
'Life changes after an ALS diagnosis,' according to the website. 'Being diagnosed with ALS is devastating and overwhelming. Learning to accept your diagnosis and live with the disease can be incredibly difficult.'
Chicago Bears Super Bowl winner Steve McMichael died earlier this week after a years-long struggle with the disease.
Tim Hughart and Thomas said Lisa's brother was also recently diagnosed with the disease.
The ALS Society provides support groups, transportation assistance and equipment.
Hughart said the society provided a wheelchair for his wife as the disease progressed.
The organization also provides suggestions on how to make home adjustment to make living with the disease easier.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
a day ago
- Los Angeles Times
Hims & Hers' ugly split with Wegovy maker weighs on the telehealth company's future
Hims & Hers, the high-flying telehealth company that rapidly ascended from a buzzy startup selling Viagra to a multibillion-dollar business with a Super Bowl ad, had a hard week. The San Francisco company's shares took a dive Monday after its partnership with Novo Nordisk crumbled. The Danish drugmaker abruptly ended its agreement to let Hims & Hers directly sell its popular weight-loss drug, prompting the companies to spar publicly. Less than two months after agreeing to partner with Hims & Hers, Novo Nordisk accused the telehealth company of putting patient safety at risk through 'deceptive' marketing and selling a knockoff version of its drug Wegovy. Hims & Hers fired back, alleging that Novo Nordisk was 'misleading the public' and wanted to 'control clinical standards and steer patients to Wegovy.' The messy split is the latest hurdle facing Hims & Hers, a platform where people subscribe to get help for hair loss, improve sex, lose weight and address other health problems. The company aims to reach $6.5 billion in revenue by 2030. The tussle also highlights the tensions between telehealth platforms and pharmaceutical companies. 'The termination of this partnership suggests that Novo still views Hims' marketing and sales tactics as a threat to branded Wegovy and indicates Novo considers Hims more of a competitor than a true partner,' Aaron DeGagne, a senior analyst of healthcare at PitchBook, said in a statement. Hims & Hers' stock price has swung wildly this year. The price had at one point soared more than 150% this year before the Novo split knocked off a nearly a third of its valuation on Monday. Its share price rose nearly 7% on Friday to end the week at $49.41. Hims & Hers is disrupting the healthcare industry, testing the limits of regulations to make it easier to buy popular drugs at lower prices. Its showdown with Novo could help define how far it can go. While Hims & Hers faces more legal risks after the breakup, some analysts said they don't expect the fallout to heavily harm the company's growth. The company is expanding beyond just treating weight loss. Still, Hims & Hers is losing a potential source of revenue. 'Even with all these revenue streams, the bigger concern (rightfully so) is the ability for these revenue streams to fill the expected hole that the end of the NovoCare partnership creates,' Michael Cherny, a senior research analyst at Leerink Partners, said in a note. NovoCare is the pharmacy people were able to access on the Hims & Hers platform to buy the weight-loss drug. Last year, Hims & Hers said in a letter to shareholders that the company expects its weight loss offerings will contribute at least $725 million of revenue in 2025 but that treatments outside of that category will make up the majority of its sales. Wegovy is just one weight-loss drug it offers. Launched in 2017, Hims initially focused on treating men's health issues such as hair loss and erectile dysfunction — concerns that people might feel too embarrassed to bring up in doctor visits. Instead, subscribers answer questions online, correspond with medical professionals virtually and get the prescribed drugs in visually pleasing packages delivered discreetly to their homes. Andrew Dudum, one of the company's co-founders and its chief executive, started Hims at venture studio Atomic in San Francisco. The startup, now known as Hims & Hers Health Inc., then expanded into women's health, went public in 2021 and grew its workforce to more than 1,600 workers. Hims & Hers' annual revenue grew from $148.8 million in 2020 to $1.48 billion in 2024. The company also became profitable with its net income reaching $126 million in 2024, compared with a loss of $18 million in 2020. The company forecasts it will reach between $2.3 billion and $2.4 billion in revenue this year. The company's growth and 2.4 million-subscriber base was turbocharged as people looked for easier access and affordable options to the wildly popular weight-loss drugs Wegovy and Ozempic. Despite strong results in the first quarter of this year, the company's forecast for second-quarter revenue fell below analysts' expectations. In May, Hims & Hers said it was slashing more than 4% of its workforce after signaling it would move away from selling cheaper alternatives to weight-loss drugs. Its stock had initially surged in February after the company released a controversial Super Bowl ad promoting its treatment for weight loss. The ad marketed the telehealth platform as an affordable solution to a system that is 'built to keep us sick and stuck.' But the company's aggressive marketing triggered backlash. Doctors, politicians and drugmakers quickly criticized the company for not disclosing the risks associated with the compounded drugs that Hims & Hers sometimes uses for weight loss. With compounded drugs, licensed pharmacists alter, mix or combine ingredients of a drug to customize medicines. Though copying patented drugs is illegal, compounded knockoffs are allowed if they are tailored for a patient who might need something slightly different than what the patent-holding company produces. For example, a person might take a compounded drug if they're allergic to a certain dye. Taking compounded drugs comes with risks, according to the U.S. Food and Drug Administration. Unlike generics, they're not approved by the FDA, a federal agency that verifies whether drugs are safe and effective . Compounding drugs is also allowed when there's a shortage of an FDA-approved drug, which has happened with Wegovy and Ozempic. But those drugs are no longer in shortage, and the FDA has warned the public about taking compounded drugs when it isn't medically necessary. The fallout between Hims & Hers and Novo Nordisk centers on its sales of compounded versions of Wegovy, a drug people inject to decrease hunger so they eat less and lose weight. In April, the two companies teamed up to make obesity treatment more affordable and accessible. Starting at $599 per month, some people were able to get prescribed to Wegovy and a Hims & Hers membership. That was much cheaper than the previous cost of paying $1,999 per month for Wegovy on the Hims & Hers platform. That partnership was short-lived. Novo Nordisk said this week that it's cutting off Hims & Hers' direct access to Wegovy. 'Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk,' Novo Nordisk said in a statement. Hims & Hers advertises a compounded drug that contains the same ingredients in Wegovy for $165 per month. Novo Nordisk, citing its own investigation and a Brookings Institution report, said ingredients in knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured in China and do not have FDA approval. Novo Nordisk sells Wegovy through its pharmacy NovoCare and telehealth platforms LifeMD and Ro. On Thursday, the company also announced a partnership with WeightWatchers to sell Wegovy at a discounted price in July. Dudum, Hims & Hers chief executive, said on social media site X that the telehealth provider would still provide a variety of treatments including Wegovy. The company says on its website that it works with pharmacies in Arizona and Ohio that are regulated. 'We refuse to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision making of providers and limit patient choice,' he said in the statement.
Business Upturn
3 days ago
- Business Upturn
Parse Biosciences GigaLab to Support Mount Sinai Researchers in Generating One of the Largest Alzheimer's and Parkinson's Single Cell Datasets
Seattle, United States: Parse Biosciences today announced their commitment to support researchers from the Icahn School of Medicine at Mount Sinai in generating one of the largest single cell datasets focused on understanding alternative splicing events in the cells of Alzheimer's and Parkinson's patients. The study's initial phase will analyze transcriptomic profiles from more than 10 million cells derived from more than 1,000 peripheral blood mononuclear cell (PBMC) samples of patients with neurodegenerative conditions. The data amassed from these analyses will lay the foundation for discoveries that could transform how these diseases are understood, detected, and treated. 'Historical research in neurodegenerative disease has focused on the genomic underpinnings for disease diagnoses, but few have looked at the post transcriptional events that may be further driving pathology and progression of disease,' said Towfique Raj, PhD, principal investigator in the laboratory for functional genomics and core faculty member of the Ronald M. Loeb Center for Alzheimer's Disease at Mount Sinai, who will lead this study. 'We're excited to be able to look at alternative splicing events in single cells at scale to determine alternative contributors to disease onset, progression and severity. Studies of this scale are critical to the development of foundational models to help us better understand neurodegenerative disease.' Dr. Raj's research team at Mount Sinai is dedicated to understanding the molecular mechanisms of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and ALS (amyotrophic lateral sclerosis). For this study, the Mount Sinai team is working to conduct high-throughput profiling on banked PBMCs donated by patients with confirmed Alzheimer's disease or Parkinson's disease diagnoses. The researchers expect to profile more than 1,000 samples in order to capture single cell whole transcriptome repertoire data on them. The samples that have been prepared at Mount Sinai will then be sent to Parse GigaLab, a state-of-the-art facility purpose-built for the generation of massive-scale single cell RNA sequencing datasets. Leveraging Parse's Evercode chemistry, the GigaLab can rapidly produce large single cell datasets with exceptional quality. 'We are incredibly excited to bring the power of GigaLab to elevate the impactful work the Raj Lab has been driving,' says Dr. Charlie Roco, Chief Technology Officer at Parse Biosciences. 'The speed and scale achieved with the GigaLab truly helps to accelerate research and get us to insights faster than we ever have before.' About Parse Biosciences Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. With technology developed at the University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $100 million in capital and is used by over 2,500 customers across the world. Its growing portfolio of products includes Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR, Gene Select, and a solution for data analysis, Trailmaker™. Parse Biosciences is based in Seattle's vibrant South Lake Union district, where it recently expanded into a new headquarters and state-of-the-art laboratory. To learn more, please visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
4 days ago
- Yahoo
Once named opponents in the Supreme Court case that legalized same-sex marriage, now they're friends
COLUMBUS, Ohio (AP) — The case behind the U.S. Supreme Court ruling legalizing same-sex marriage nationwide a decade ago is known as Obergefell v. Hodges, but the two Ohio men whose names became that title weren't so at odds as it would seem, and are now friends. One year after the Supreme Court's June 26, 2015, decision, lead plaintiff Jim Obergefell was at an event for an LGBTQ+ advocacy organization when its former director asked if he wanted to meet Rick Hodges, who'd been the title defendant in his capacity as state health director in Ohio, one of the states challenged for not allowing same-sex couples to marry. 'I don't know, you tell me. Do I want to meet Rick Hodges?" Obergefell recalls responding. The two met for coffee in a hotel and hit it off. Hodges said he wanted to meet Obergefell because he's an 'icon.' He said he remembers telling Obergefell something along the lines of: 'I don't know if congratulations are in order because this began with you losing your husband, but I'm glad you won and I've never been so happy to lose in my life.' Obergefell and John Arthur, who brought the initial legal action, were longtime partners living in Cincinnati. After Arthur was diagnosed with ALS, or amyotrophic lateral sclerosis, in 2011, Obergefell became Arthur's caregiver as the incurable condition ravaged his health. They flew to Maryland to marry before Arthur died in 2013, and the legal battle began when they learned their union wouldn't be listed on the death certificate handled by the Ohio Department of Health. Although Hodges' role as health director required him to defend the state, it didn't mean that his personal views aligned with the state's position. 'Personally, I was supportive of their efforts, as were some of the people who worked on the case for the state. Professionally, I had a job to do and I did it to the best of my ability," Hodges said. In the months leading up to the court's decision, Hodges had gathered a group of Ohio lawyers to develop the paperwork needed to create the licensing system for judges to grant same-sex couples marriage licenses on the day of the decision if the Supreme Court ruled in their favor, said Obergefell's lead attorney in the case, Al Gerhardstein. Gerhardstein said Obergefell and Hodge's friendship is unusual in a 'very positive and exemplary way.' 'We need more models like that as we struggle with difficult social issues," he said. The duo said they see each other two to three times per year and have routinely spoken together at conferences and panels. 'It's funny, whenever we go into an event together, everybody claps for him and looks at me like I'm the prince of darkness until we're done, and then it's great," Hodges said. They are seeing each other more often this year since it's the 10th anniversary of the decision. Recently, they saw each other at a symposium at Northern Kentucky University and at another event, sponsored by Equality Ohio, the same organization that first led to their introduction. 'I can't think of other cases where the plaintiff and the defendant are friends. They might exist, I don't know about them," Obergefell said. "But I'm really glad that Rick and I are friends.'
